Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SMS Shareholders To Consider Eclipsys-Nominated Slate Of Directors May 16

This article was originally published in The Gray Sheet

Executive Summary

Shared Medical Systems' May 16 annual shareholder meeting agenda will include consideration of a rebel slate of director candidates to be nominated by rebuffed suitor Eclipsys.

You may also be interested in...



Eclipsys Ends SMS Takeover Bid After Agreeing To Neoforma.com Merger

Eclipsys effectively ended its takeover bid for rival healthcare IT provider Shared Medical Systems by withdrawing plans to propose a rebel slate of director candidates at SMS' annual shareholder meeting, following its decision to merge with online medical supply company Neoforma.com.

Eclipsys Ends SMS Takeover Bid After Agreeing To Neoforma.com Merger

Eclipsys effectively ended its takeover bid for rival healthcare IT provider Shared Medical Systems by withdrawing plans to propose a rebel slate of director candidates at SMS' annual shareholder meeting, following its decision to merge with online medical supply company Neoforma.com.

Shared Medical Systems Corp.

Anti-takeover shareholder rights plan is amended to delete all provisions requiring certain actions under the plan to be authorized by "continuing directors," the firm announces March 20. The order was taken to "conform the terms of the plan to recent decisions by the Delaware courts." Rebuffed suitor Eclipsys, which launched an unsolicited $2 bil. merger proposal March 2, had filed suit in Delaware Chancery Court challenging the legality of the "continuing director provision" of SMS' "poison pill" shareholder rights plan (1"The Gray Sheet" March 13, p. 14). SMS has scheduled its annual shareholders meeting for June 9, instead of May 16 as previously anticipated, to allow more time for the firm to evaluate various strategic alternatives

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel